Latest Articles

30. 11. 2018

List of reimbursed medicinal products valid as of 1.12.2018

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...

 

13. 11. 2018

Waiver of Reimbursement of Costs for Additional Strengths/Pharmaceutical Forms of a Particular Product upon Take-over of the Role of the RMS Due to Brexit

Upon request, SÚKL shall waive the payment of reimbursement of costs for additional strengths/pharmaceutical forms of a medicinal product in respect of which it will take...

 

31. 10. 2018

List of reimbursed medicinal products valid as of 1.11.2018

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...

 

30. 10. 2018

Notice to applicants for placing of foreign language batch of a medicinal product on the market

Notice to applicants on requirements to permit the placing of foreign language batch of a medicinal product on the market in the Czech Republic.

 

27. 09. 2018

List of reimbursed medicinal products valid as of 1.10.2018

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...

 

31. 08. 2018

List of reimbursed medicinal products valid as of 1.9.2018

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...

 

31. 07. 2018

List of reimbursed medicinal products valid as of 1.8.2018

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...

 

03. 07. 2018

Sunset Clause Application to Generic Medicinal Products

Notification of marketing authorisation holders regarding the calculation of the 3-year period for placement on the market of a generic medicinal product only as of 1...